Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06943469

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 day–14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AZ Sint-Jan Brugge-Oostende AV - Campus Sint-Jan, Bruges, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent has been obtained from at least one parent or legally acceptable representative (LAR), if applicable
  • Infant gestational age ≥ 37 completed weeks
  • Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg
  • Infant postnatal age ≤ 14 days (date of birth = day 0) at enrollment
  • Infant from singleton birth or infant from multiple births may if all birth siblings are enrolled.
  • At least one biological parent or sibling has (or had) a medically diagnosed history of allergy, based on response to a simple screening questionnaire
  • a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age.

or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.

  • Parents/LAR must be able to provide evidence of parental authority and identity.
  • Infant's parent(s)/LAR must understand the informed consent form and other study documents and are willing and able to fulfill the requirements of the study protocol.

Exclusion criteria

  • Infectious, metabolic, congenital, genetic, gastrointestinal illness or any other condition (e.g., gastrointestinal surgery) that could impact oral feeding, growth or study outcomes.
  • Infants with special dietary needs other than standard infant formula (e.g., extensively hydrolyzed formula, amino acid formula, special formula for metabolic diseases) or requiring tube feeding.
  • Infant has already been diagnosed with allergy by a physician, including AD and/or cow's milk allergy.
  • Infant is currently participating or has previously participated in another clinical trial prior to enrollment.
  • Infant's parents or LARs have not reached legal age of majority (18 years).

Treatment and study plan

Test formula

Other

Partially hydrolyzed formula with synbiotics

Control Formula

Other

Intact protein formula without synbiotics

Primary outcomes

  1. TransEpidermal Water Loss (TEWL) at 3 months

    Time frame: At 3 months of age

    TransEpidermal water loss will be measured using a validated non-invasive technique.

Secondary outcomes

  1. Cumulative incidence of Atopic Dermatitis

    Time frame: From enrollment to 12 months of age

    Cumulative incidence of AD is based on physician diagnosis using the United Kingdom Working Party (UKWP) diagnosis criteria.

  2. TransEpidermal Water Loss

    Time frame: From enrollment to 12 months of age

    Epidermal water loss will be measured using a validated non-invasive technique.

  3. Skin surface (stratum corneum) hydration

    Time frame: From enrollment to 12 months of age

    Skin hydration will be measured with a corneometer device.

  4. Extent and severity of Atopic Dermatitis

    Time frame: From 3 months to 12 months of age

    SCORAD (SCORing for Atopic Dermatitis), scores range from 0 to 103, with higher scores indicating higher atopic dermatitis severity

  5. Cumulative use of topical steroids and calcineurin inhibitors

    Time frame: From enrollment to 12 months of age

    Use of medication to treat AD and other symptoms will be collected via parent self-reported questionnaire.

  6. Skin cytokines

    Time frame: From enrollment to 12 months of age

    Concentration of skin cytokines such as IL4 and IL5 using immunoassays

  7. Skin natural moisturizing factors

    Time frame: From enrollment to 12 months of age

    Concentration of skin natural moisturizing factors such as Pyrrolidone carboxylic acid, using HPLC

  8. Skin stratum corneum lipids

    Time frame: From enrollment to 12 months of age

    Concentration of skin stratum corneum lipids such as ceramides, cholesterol and triacylglycerol using mass spectrometry

  9. Skin microbiome

    Time frame: From enrollment to 12 months of age

    Overall skin microbiome composition and diversity using next-generation sequencing

  10. Skin metabolites

    Time frame: From enrollment to 12 months of age

    Levels of skin metabolites using targeted or untargeted approaches.

  11. Immune proteomics

    Time frame: From enrollment to 6 months of age

    Levels of plasma proteins using mass cytometry or immunoassaysand immunoassays.

  12. Immune blood cell immunophenotyping

    Time frame: From enrollment to 6 months of age

    Levels of immune cell populations using mass cytometry or immunoassays

  13. Specific IgE antibodies

    Time frame: At 12 months of age

    Specific IgE antibodies will be measured using Phadiatop infant®.

  14. Fecal microbiome

    Time frame: From enrollment to 12 months of age

    Overall fecal microbiota composition, diversity, different bacteria taxa and microbiota community types assessed using next generation sequencing (NGS) technology

  15. Fecal metabolites

    Time frame: From enrollment to 12 months of age

    Levels of fecal metabolites using targeted or untargeted approaches.

  16. Fecal biomarkers of inflammation and immunity

    Time frame: From enrollment to 12 months of age

    Levels of fecal markers of immune health and inflammation such as total secretory IgA (sIgA), calprotectin, and α-1-antitrypsin assessed by ELISA.

  17. Physician-diagnosed allergic manifestations

    Time frame: From enrollment to 12 months of age

    Number of participants with Physician-diagnosed allergic manifestations.

  18. Gastrointestinal tolerance

    Time frame: At enrollment and 4 months of age

    Infant Gastrointestinal Symptom Questionnaire (IGSQ), scores range from 13 to 65, with higher scores indicating higher gastrointestinal discomfort.

  19. Weight

    Time frame: From enrollment to 12 months of age

    Weight (g and z-scores)

  20. Height

    Time frame: From enrollment to 12 months of age

    Length (cm and z-scores)

  21. Head circumference

    Time frame: From enrollment to 12 months of age

    Head circumference (cm and z-scores)

  22. Safety assessment

    Time frame: From enrollment to 13 months of age

    Incidence of adverse events

Study contacts

Contact information is provided by the study sponsor or research team.

Amelie Goyer, PhD

CONTACT

[email protected]

+41217858939

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Official study title

Synbiotics in Partially Hydrolysed Formula for Improved skiN Barrier Function in Infants at Risk for Allergy (SPHINX Study)

Acronym: SPHINX

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Apr 24, 2025
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.